- Business
- Fabino Enterprises Ltd. (FABINO.BO) is an India-based pharmaceutical company that develops, manufactures, markets, trades, and packages a broad range of pharmaceutical formulations and wellness-focused consumer products, including allopathic tablets and injectables such as AMOXRAG-625, Aur D3 Capsules, Aurceta AM, Aurcis-Forte, Aurifox OZ, Aurimor Gold, Aurimor Plus, Aurirug 200, Aurirug O, Aurnim Plus, Aurstin 250, Aurstin 500, Aurzyme Syrup, Ayush Kadha, Calogrip, Cefga 1gm, Cekal Forte, Ceporag O, Coptec Capsules, Coptec Syrup, Cough-Free, Dexrog Syrup, Dicarag Gel, Dicpa, Doref DS, Doref M, Dr-DSR, DStoren Syrup, Ecstasy Tilla Oil, F Plexus A, Fablactin, Fabovit, Fabpara, Fabvit C, FABZYM Capsule, Giloy Power, Glucose, Iorag-XT, M-Sharp Brain Tonic, Mefdic, Misar-40, Misar-H; herbal, veterinary, multi-vitamin, and Covid-19 related products; as well as food and wellness items under the Fabino and Keepshine brand names, such as 21 No Tea, Fab Cafe, Fabvita Malt Protein, Keepshine Hair Oil, Keepshine Shampoo, Massage Oil, and Juicy Jo fruit-flavored drinks including Lychee, Mango, Guava, Jeera, and Nimbu Paani; it also exports wellness and fast-moving consumer goods (FMCG) products like coffee, malt powder, protein powder, and hair shampoo. The company sources active pharmaceutical ingredients (APIs), undertakes third-party manufacturing for herbal and food supplements, and recently expanded into bio agro fertilizers and bio pesticides, while sourcing ayurvedic formulations through loan licensing facilities for packing and labeling. Fabino Enterprises Ltd. primarily serves the domestic Indian market through its own distribution network and sales force, with all sales concentrated in India as of fiscal year 2024, and exports select wellness and FMCG products to customers worldwide. Incorporated in 2011 and headquartered in Sonipat, India, at Jeevan Vihar Extension, Murthal Road, the company changed its name from Fabino Life Sciences Limited to Fabino Enterprises Limited in June 2024 to reflect its broadened scope beyond pure life sciences into diversified enterprises.